JP6564372B2 - バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 - Google Patents

バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 Download PDF

Info

Publication number
JP6564372B2
JP6564372B2 JP2016536495A JP2016536495A JP6564372B2 JP 6564372 B2 JP6564372 B2 JP 6564372B2 JP 2016536495 A JP2016536495 A JP 2016536495A JP 2016536495 A JP2016536495 A JP 2016536495A JP 6564372 B2 JP6564372 B2 JP 6564372B2
Authority
JP
Japan
Prior art keywords
patient
medicament according
patients
compound
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016536495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528300A5 (https=
JP2016528300A (ja
Inventor
メラニー ペイ−ヘン チン
メラニー ペイ−ヘン チン
コリン ジェイ． メイヤー
コリン ジェイ． メイヤー
Original Assignee
リアタ ファーマシューティカルズ インコーポレイテッド
リアタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リアタ ファーマシューティカルズ インコーポレイテッド, リアタ ファーマシューティカルズ インコーポレイテッド filed Critical リアタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2016528300A publication Critical patent/JP2016528300A/ja
Publication of JP2016528300A5 publication Critical patent/JP2016528300A5/ja
Application granted granted Critical
Publication of JP6564372B2 publication Critical patent/JP6564372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2016536495A 2013-08-23 2014-08-22 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 Active JP6564372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869527P 2013-08-23 2013-08-23
US61/869,527 2013-08-23
PCT/US2014/052382 WO2015027206A1 (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018220800A Division JP6526306B2 (ja) 2013-08-23 2018-11-27 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法

Publications (3)

Publication Number Publication Date
JP2016528300A JP2016528300A (ja) 2016-09-15
JP2016528300A5 JP2016528300A5 (https=) 2017-09-28
JP6564372B2 true JP6564372B2 (ja) 2019-08-21

Family

ID=51794949

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016536495A Active JP6564372B2 (ja) 2013-08-23 2014-08-22 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
JP2018220800A Active JP6526306B2 (ja) 2013-08-23 2018-11-27 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
JP2019074559A Active JP6701407B2 (ja) 2013-08-23 2019-04-10 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018220800A Active JP6526306B2 (ja) 2013-08-23 2018-11-27 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
JP2019074559A Active JP6701407B2 (ja) 2013-08-23 2019-04-10 バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法

Country Status (18)

Country Link
US (3) US20150080465A1 (https=)
EP (2) EP4736949A2 (https=)
JP (3) JP6564372B2 (https=)
KR (1) KR102322057B1 (https=)
CN (2) CN105517554B (https=)
AU (2) AU2014308600B2 (https=)
BR (1) BR112016003454B1 (https=)
CA (1) CA2921386A1 (https=)
CL (1) CL2016000405A1 (https=)
EA (1) EA201690456A1 (https=)
IL (3) IL285832B2 (https=)
MX (2) MX380589B (https=)
MY (2) MY198522A (https=)
NZ (4) NZ744036A (https=)
PH (1) PH12016500358B1 (https=)
SG (2) SG11201601202WA (https=)
TW (2) TWI716341B (https=)
WO (1) WO2015027206A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
TWI623548B (zh) 2012-04-27 2018-05-11 瑞塔醫藥有限責任公司 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
JP6243428B2 (ja) 2012-09-10 2017-12-06 リアタ ファーマシューティカルズ インコーポレイテッド オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
EP4736949A2 (en) * 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3256451B1 (en) 2015-02-12 2021-10-20 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018200692A1 (en) * 2017-04-26 2018-11-01 The Trustees Of The University Of Pennsylvania Methods and systems for virtual and augmented reality training for responding to emergency conditions
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
MX2021003643A (es) * 2018-09-28 2021-08-19 Sichuan Haisco Pharmaceutical Co Ltd Derivados de terpenoides y usos de los mismos.
WO2020080482A1 (ja) * 2018-10-17 2020-04-23 株式会社 資生堂 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法
EP3999522B1 (en) * 2019-07-19 2025-09-03 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
WO2021104391A1 (zh) * 2019-11-27 2021-06-03 鲁南制药集团股份有限公司 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CA3164676A1 (en) * 2019-12-23 2021-07-01 Toray Industries, Inc. Drug for preventing dialysis shift or renal death
WO2021202720A1 (en) * 2020-04-01 2021-10-07 Fronthera U.S. Pharmaceuticals Llc Use of triterpenoid nrf2 inhibitors
BR112022022599A2 (pt) * 2020-05-09 2023-03-21 Reata Pharmaceuticals Holdings Llc Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
US12064409B2 (en) 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
ES2401741T3 (es) 2007-05-08 2013-04-24 Abbott Laboratories Ensayo de péptido natriurético de tipo B humano que tiene una reducida reactividad cruzada con otras formas péptidicas
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
BRPI0907423A2 (pt) * 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) * 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2558105T3 (da) * 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
EP4736949A2 (en) * 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
IL285832B1 (en) 2023-09-01
JP6526306B2 (ja) 2019-06-05
TW202026003A (zh) 2020-07-16
TWI716341B (zh) 2021-01-21
JP2019131599A (ja) 2019-08-08
IL244171A0 (en) 2016-04-21
AU2014308600A1 (en) 2016-03-03
US20150080465A1 (en) 2015-03-19
EP4736949A2 (en) 2026-05-06
EP3035937A1 (en) 2016-06-29
CL2016000405A1 (es) 2017-02-24
CN105517554B (zh) 2021-01-15
JP2019048873A (ja) 2019-03-28
MX380589B (es) 2025-03-12
KR20160061994A (ko) 2016-06-01
IL285832B2 (en) 2024-01-01
AU2014308600B2 (en) 2020-03-05
CA2921386A1 (en) 2015-02-26
NZ756256A (en) 2021-07-30
IL272242B (en) 2021-09-30
SG11201601202WA (en) 2016-03-30
AU2020203510A1 (en) 2020-06-18
BR112016003454B1 (pt) 2023-02-14
CN105517554A (zh) 2016-04-20
WO2015027206A1 (en) 2015-02-26
NZ774222A (en) 2023-01-27
BR112016003454A2 (pt) 2017-08-01
MY198522A (en) 2023-09-04
IL285832A (en) 2021-09-30
EA201690456A1 (ru) 2016-06-30
WO2015027206A8 (en) 2015-06-11
PH12016500358B1 (en) 2023-08-16
US20190091194A1 (en) 2019-03-28
IL244171B (en) 2020-02-27
US20240115542A1 (en) 2024-04-11
MX2021002897A (es) 2021-06-08
PH12016500358A1 (en) 2016-05-16
HK1223015A1 (zh) 2017-07-21
MX2016002375A (es) 2016-12-20
CN112870202A (zh) 2021-06-01
SG10201906113RA (en) 2019-08-27
JP6701407B2 (ja) 2020-05-27
TWI717026B (zh) 2021-01-21
NZ630951A (en) 2018-09-28
AU2020203510B2 (en) 2023-05-11
IL272242A (en) 2020-02-27
NZ744036A (en) 2020-09-25
KR102322057B1 (ko) 2021-11-05
EP3035937B1 (en) 2025-12-31
JP2016528300A (ja) 2016-09-15
MY205497A (en) 2024-10-23
TW201542211A (zh) 2015-11-16

Similar Documents

Publication Publication Date Title
JP6701407B2 (ja) バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
JP6633812B2 (ja) バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
JP2023526567A (ja) バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法
JP7421815B2 (ja) 心不全の治療のための１７ベータ－複素環ジギタリス類似化合物
CN114072205A (zh) 用tie-2激活剂治疗高血压的方法
HK40052300A (en) Methods of treating and preventing a renal disease using bardoxolone methyl or analogs thereof
EA042085B1 (ru) Способ лечения и предотвращения заболевания почек
HK1223015B (zh) 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法
HK40011743A (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
HK40011743B (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180816

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20181109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190726

R150 Certificate of patent or registration of utility model

Ref document number: 6564372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250